NRX Pharmaceuticals (NRXP) Total Current Liabilities (2017 - 2026)
NRX Pharmaceuticals (NRXP) posted quarterly Total Current Liabilities of $25.2 million for Q1 2026, down 23.13% year-over-year from $32.8 million in Q1 2025, and down 11.9% quarter-over-quarter from $28.6 million in Q4 2025.
NRX Pharmaceuticals (NRXP) Total Current Liabilities (2017 - 2026) Analysis & Trends
NRX Pharmaceuticals (NRXP) has reported Total Current Liabilities for 10 consecutive years, with $25.2 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Total Current Liabilities fell 23.13% year-over-year to $25.2 million; the TTM figure through Mar 2026 stood at $25.2 million (down 23.13% YoY), while the FY2025 annual figure was $28.6 million, up 30.71% from the prior year.
- Total Current Liabilities retreated to $25.2 million in Q1 2026 per NRXP's latest filing, from $28.6 million in the prior quarter.
- Across five years, Total Current Liabilities topped out at $40.6 million in Q3 2025 and bottomed at $15.6 million in Q4 2022.
- Historically, Total Current Liabilities has averaged $25.7 million across 5 years, with a median of $22.3 million in 2023.
- Annual changes were most pronounced in 2025 — Total Current Liabilities surged 99.98% — and 2026, when it declined 23.13%.
- NRX Pharmaceuticals' Total Current Liabilities stood at $15.6 million in 2022, then climbed by 22.22% to $19.0 million in 2023, then increased by 14.78% to $21.9 million in 2024, then soared by 30.71% to $28.6 million in 2025, then decreased by 11.9% to $25.2 million in 2026.
- Business Quant data shows NRXP's Total Current Liabilities at $25.2 million in Q1 2026, $28.6 million in Q4 2025, and $40.6 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 140.01 Bn | 132.16 Bn | 2.84 Bn | 3.94 Bn |
| 2 | Regeneron Pharmaceuticals | 86.79 Bn | 78.79 Bn | 3.93 Bn | 5.53 Bn |
| 3 | Argenx Se | 65.29 Bn | 60.11 Bn | 1.37 Bn | 1.58 Bn |
| 4 | Moderna | 60.18 Bn | 55.04 Bn | 52.00 Mn | 2.53 Bn |
| 5 | BeOne Medicines | 42.17 Bn | 37.07 Bn | 1.53 Bn | 2.12 Bn |
| 6 | Alnylam Pharmaceuticals | 31.55 Bn | 28.24 Bn | 992.69 Mn | 1.51 Bn |
| 7 | BioNTech SE | 28.45 Bn | 10.06 Bn | 668.28 Mn | 2.49 Bn |
| 8 | Insmed | 27.45 Bn | 26.29 Bn | 358.27 Mn | 438.74 Mn |
| 9 | Royalty Pharma | 27.19 Bn | 26.36 Bn | - | 630.93 Mn |
| 10 | NRX Pharmaceuticals | 132.75 Mn | 106.05 Mn | 426,000.00 | 33.87 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 25.18 Mn |
| Dec 31, 2025 | 28.58 Mn |
| Sep 30, 2025 | 40.59 Mn |
| Jun 30, 2025 | 40.45 Mn |
| Mar 31, 2025 | 32.75 Mn |
| Dec 31, 2024 | 21.86 Mn |
| Sep 30, 2024 | 20.30 Mn |
| Dec 31, 2023 | 19.05 Mn |
| Sep 30, 2023 | 19.33 Mn |
| Jun 30, 2023 | 22.62 Mn |
| Mar 31, 2023 | 22.06 Mn |
| Dec 31, 2022 | 15.59 Mn |
| Dec 31, 2021 | 11.92 Mn |
| Sep 30, 2021 | 36.77 Mn |
| Jun 30, 2021 | 57.80 Mn |
| Dec 31, 2020 | 46.16 Mn |
| Sep 30, 2020 | 379,198.00 |
| Jun 30, 2020 | 297,238.00 |
| Mar 31, 2020 | 316,381.00 |
| Dec 31, 2019 | 622,441.00 |